Crossref
An AI-Guided Biparatopic DLL3-Targeting ADC Demonstrates Enhanced Preclinical Efficacy
European Journal of Cancer · 2026-11 · 248 · 117503
DOI: 10.1016/j.ejca.2026.117503 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Y. Wu und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wu, Y., He, Y., Jiang, S., Tian, J., Shang, Y., Liu, D., Chen, Z., Shen, R., Tian, L., Ran, H., Peng, J., & Zhu, Z. (2026). An AI-Guided Biparatopic DLL3-Targeting ADC Demonstrates Enhanced Preclinical Efficacy. European Journal of Cancer, 248, 117503. https://doi.org/10.1016/j.ejca.2026.117503
Vancouver
Wu Y, He Y, Jiang S, Tian J, Shang Y, Liu D, et al. An AI-Guided Biparatopic DLL3-Targeting ADC Demonstrates Enhanced Preclinical Efficacy. European Journal of Cancer. 2026;248:117503. doi:10.1016/j.ejca.2026.117503
BibTeX
@article{Wu2026,
author = {Wu, Y. and He, Y. and Jiang, S. and Tian, J. and Shang, Y. and Liu, D. and Chen, Z. and Shen, R. and Tian, L. and Ran, H. and Peng, J. and Zhu, Z.},
title = {An AI-Guided Biparatopic DLL3-Targeting ADC Demonstrates Enhanced Preclinical Efficacy},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117503},
doi = {10.1016/j.ejca.2026.117503}
}
EUVIMED